Along with the wave of breakthrough innovation in Car-T, Cell Gene and Curative therapies, there is also an acute need for pricing innovation to pay for it. How will payers and government balance cost constraints against customer pressure to create access for potentially life-changing innovation? Even if we agree new value models, can stakeholder fragmentation be overcome to ensure implementation?
Find out from our panel of US market access leaders how they’re leading the way for a value model that supports breakthrough innovation.
When you attend, you’ll learn:
- How affordability is holding back access to innovation in the USA
- Insights into how they value and reimburse high-cost curative therapies that can transform patient lives
- Ways that payers and pharma can work together to address affordability and create patient access